Related Experiment Video
Updated: Aug 26, 2025

Author Spotlight: Illuminating New Avenues for Adipose Tissue Metabolism and Disease Prevention
Published on: October 6, 2023
Potential for Novel Therapeutic Uses of Alpha Lipoic Acid
Babatunde Fasipe1, Andre Faria2, Ismail Laher3
1Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, Bowen University, Iwo, Nigeria.
Abstract:
Alpha-lipoic acid (ALA) is a potent antioxidant used in the management of diabetic neuropathy due to its ability to prevent neuronal lipid peroxidation. ALA also chelates transition metals, which can be beneficial in some diseases related to metal overload. Due to its unique antioxidant properties, ALA has potential novel applications in other diseases related to oxidative stress and inflammation. This review summarizes aspects of recent clinical trials and describes the uses of ALA in managing neuropathies. The unique pharmacological actions of ALA, coupled with relatively low toxicity, have led to several trials on the potential therapeutic uses of ALA in the management of diseases associated with increased oxidative stress, inflammation, and metal overload.
Related Concept Videos
Alzheimer's Disease: Treatment
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

